The Pharmacokinetics and Pharmacodynamics of a Single Acute Dose of a Hemp-derived Oral Product With a 1:1 Ratio of CBD:CBD-A

Phase 1 Completed 21 enrolled Johns Hopkins University Cultivate Biologics · collab

RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to examine the pharmacokinetics and pharmacodynamics of a hemp-derived oral product containing cannabidiol (CBD) and cannabidiolic acid (CBD-A) at a 1:1 ratio.

Timeline

Start: 2022-03-07
Primary completion: 2023-06-01
Completion: 2023-06-01

Publications

Elder HJ, Zamarripa CA, Klausner M, Wakshlag J, Davis R, Dresser B, Kjaer C, Weerts EM, Vandrey R, Spindle TR. The Pharmacokinetics and Pharmacodynamics of a Hemp-Derived "Full-Spectrum" Oral Cannabinoid Product with a 1:1 Ratio of Cannabidiol to Cannabidiolic Acid and Delta-9-Tetrahydrocannabinol to Delta-9-Tetrahydrocannabinolic Acid: A Double-Blind, Placebo-Controlled, Within-Subjects Human Laboratory Study. Cannabis Cannabinoid Res. 2025 Apr;10(2):e299-e313. doi: 10.1089/can.2024.0187. Epub 2025 Mar 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cannabidiol	Other / unclassified	1 mg/kg	Oral
Subject	Cannabidiol	Other / unclassified	2 mg/kg	Oral
Subject	Cannabidiol	Other / unclassified	4 mg/kg	Oral

Indications

No indication recorded.